Compare Phillips 66 (PSX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs ResMed Inc. — how do they compare? Phillips 66 trades at $211.8 (market cap $85.11B), while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: Phillips 66 is far larger — about 3× ResMed Inc.'s market cap, and Phillips 66 pays the higher dividend (2.39%). Which is the better fit depends on your goals.
| PSX | RMD | |
|---|---|---|
Market Cap | $85.11B | $28.40B |
Sector | Energy | Health |
52-Week High | $212.27 | $293.73 |
52-Week Low | $118.37 | $182.82 |
Enterprise Value | $107.08B | $27.58B |
Dividend Yield | 2.39% | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $212.27, up 2.62% today, with a bullish technical signal and strong analyst support. Recent earnings beats, including Q1 2026's positive surprise, highlight operational strength amid volatile energy markets. The stock benefits from robust refining margins and disciplined capital returns, including a $1.27 quarterly dividend. Valuation metrics like a P/E of 20.63 and P/S of 0.63 suggest relative affordability compared to sector peers.
Outlook remains positive due to tight fuel markets and efficient refining operations, though risks include oil price volatility and declining revenue trends. With 57% of analysts rating it a buy and a consensus price target of $201.50, the stock offers upside potential, but investors should monitor debt levels and macroeconomic pressures on energy demand.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
